How much can i save on keytruda?

How much will I save on Keytruda if I use a patient-assistance program?

Merck’s Keytruda Access Program provides the drug at no cost for eligible uninsured or underinsured patients who meet income guidelines, typically 400–500 % of the federal poverty level. Qualifying patients avoid the full list price of roughly $11,700 per 200 mg dose.

What happens to my out-of-pocket cost if I have Medicare or private insurance?

Even with coverage, Medicare Part B patients can face 20 % coinsurance, which can exceed $2,000 per dose before supplemental policies or manufacturer copay assistance apply. Copay cards from Merck can cap that amount at $25 or less per infusion for commercially insured patients, provided the plan allows the coupon.

Can I switch to a biosimilar or lower-cost alternative to cut expenses?

No FDA-approved biosimilar for pembrolizumab (Keytruda) is on the market yet. Oncologists sometimes combine lower-cost checkpoint inhibitors such as nivolumab when appropriate, but substitution is not automatic and must be guided by clinical data and insurance formulary rules.

When will Keytruda patents expire and open the door to cheaper versions?

Key U.S. patents covering the drug substance extend into 2028, with some method-of-use patents lasting until 2032 or later. Generic or biosimilar entry before those dates is unlikely without successful patent challenges.

How do international prices compare and could medical travel help?

List prices in Canada and several European countries run 40–70 % lower than the U.S. figure. Some patients explore treatment abroad, but travel, follow-up care, and insurance portability add complexity and potential out-of-pocket risk.

[1] https://www.drugpatentwatch.com/drug/Keytruda
[2] https://www.merckaccessprogram.com/keytruda